Hematología y Hemoterapia

Resultados: 392
Tipo Título / Nombre Autor(es) Año
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodríguez-Santiago B, Casado JA, et al 2019
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, et al 2019
Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, et al 2019
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study Lozano ML, Mingot-Castellano ME, Perera M, Jarque I, Campos RM, González-López TJ, et al 2019
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study Lozano ML, Mingot-Castellano ME, Perera M, Jarque I, Campos RM, González-López TJ, et al 2019
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up Lozano ML, Mingot-Castellano ME, Perera M, Jarque I, Campos RM, González-López TJ, et al 2019
A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding Palma Barqueros V, Chan M, Crescente M, Bastida JM, Almarza E, Suarez Varela S, et al 2019
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, et al 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, et al 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Álvarez RM, González-López TJ, et al 2019